Tempered Forward Expectations Hurt Repligen Corp. (RGEN) in Q1

1 hour ago 1

Soumya Eswaran

Mon, April 27, 2026 astatine 9:26 AM CDT 3 min read

Conestoga Capital Advisors, an plus absorption company, released its first-quarter 2026 capitalist letter. A transcript of the missive tin beryllium downloaded here. The archetypal 4th of 2026 began with optimism astir the home system and charismatic Small Cap valuations, but was impacted by volatility from Middle East geopolitical unrest and changing involvement complaint expectations. This unrest drove vigor prices up and created cautious planetary markets. Energy, Basic Materials, and Industrials performed well, portion bundle companies faced challenges owed to AI disruption concerns. Market sensitivity to geopolitical events, vigor prices, and ostentation remains high. The Conestoga Small Cap Composite fell 5.01%, underperforming the Russell 2000 Growth’s -2.81% return. The diminution was driven by antagonistic banal enactment and headwinds successful Technology and Health Care, with assemblage allocation benefits insufficient to offset losses. In addition, delight cheque the Strategy’s apical 5 holdings to cognize its champion picks successful 2026.

In its first-quarter 2026 capitalist letter, Conestoga Capital Advisors highlighted stocks similar Repligen Corporation (NASDAQ:RGEN). Repligen Corporation (NASDAQ:RGEN) is simply a beingness subject institution that develops and distributes bioprocessing technologies and systems. On April 24, 2026, Repligen Corporation (NASDAQ:RGEN) closed astatine $117.60 per share. One-month instrumentality of Repligen Corporation (NASDAQ:RGEN) was 6.63%, and its shares mislaid 18.12% implicit the past 52 weeks. Repligen Corporation (NASDAQ:RGEN) has a marketplace capitalization of $6.63 billion.

Conestoga Capital Advisors stated the pursuing regarding Repligen Corporation (NASDAQ:RGEN) successful its Q1 2026 capitalist letter:

"Repligen Corporation (NASDAQ:RGEN) develops bioprocessing technologies utilized successful the accumulation of biologic drugs. Despite a coagulated quarter, the banal underperformed arsenic investors focused connected a much measured outlook and lingering concerns astir extremity marketplace demand. While the institution delivered 14% integrated growth, guidance for 2026 called for a much mean maturation scope and incorporated headwinds successful cistron therapy. The operation of beardown caller show but tempered guardant expectations led to a much cautious capitalist response."

Is Repligen Corporation (RGEN) the Top Stock to Buy According to 12 West Capital Management?

Repligen Corporation (NASDAQ:RGEN) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 43 hedge money portfolios held Repligen Corporation (NASDAQ:RGEN) astatine the extremity of the 4th quarter, compared to 53 successful the erstwhile quarter. In Q4 2025, Repligen Corporation (NASDAQ:RGEN) reported revenue of $198 million, marking an summation of 18% twelvemonth implicit year. While we admit the imaginable of Repligen Corporation (NASDAQ:RGEN) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article